Upstream Bio (UPB) Total Current Liabilities (2023 - 2026)

Upstream Bio's Total Current Liabilities history runs 4 years deep, the most recent figure standing at $13.7 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 42.88% year-over-year to $13.7 million in Q1 2026; TTM through Mar 2026 was $13.7 million, a 42.88% increase from a year earlier, with the FY2025 full-year figure at $13.5 million, up 25.29% from the prior year.
• Total Current Liabilities rose to $13.7 million in Q1 2026 per UPB's latest filing, from $13.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $13.7 million in Q1 2026 and bottomed at $6.5 million in Q4 2023.
• The 4-year median for Total Current Liabilities is $10.9 million (2024), against an average of $11.0 million.
• Across the five-year window, Total Current Liabilities jumped 64.8% in 2024 and climbed 9.51% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $6.5 million in 2023, then soared by 64.8% to $10.7 million in 2024, then grew by 25.29% to $13.5 million in 2025, then advanced by 1.61% to $13.7 million in 2026.
• Per Business Quant, the three latest UPB Total Current Liabilities figures stand at $13.7 million (Q1 2026), $13.5 million (Q4 2025), and $11.9 million (Q3 2025).